Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy
Acta Neuropathologica · 14.10.2024 · 148 (1)
DOI: 10.1007/s00401-024-02805-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 14.10.2024. Verfasst von Ellen Gelpi und 52 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Tauopathies, Brain Stem, tau Proteins, Cell Adhesion Molecules, Neuronal. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Bundesministerium für Bildung und Forschung, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Anti-IgLON5 disease is a unique condition that bridges autoimmunity and neurodegeneration. Since its initial description 10 years ago, an increasing number of autopsies has led to the observation of a broader spectrum of neuropathologies underlying a particular constellation of clinical symptoms. In this study, we describe the neuropathological findings in 22 patients with anti-IgLON5 disease from 9 different European centers. In 15 patients (68%), we observed a hypothalamic and brainstem-predominant tauopathy of varying severity in which the original research neuropathological criteria were readily applicable. This pathology was observed in younger patients (median age at onset 61 years) with a long disease duration (median 9 years). In contrast, in 7 (32%) patients, the originally described brainstem tauopathy was nearly absent or only minimal in the form of delicate threads, despite mild-to-moderate neurodegenerative features, consistent clinical symptoms and the presence of anti-IgLON5 antibodies in CSF and serum. These patients were older at onset (median 79 years) and had shorter disease duration (median < 1 year). Overall, about one-third of the patients showed concomitant TDP-43 pathology within the regions affected by tau pathology and/or neurodegeneration. Based on these observations and in view of the spectrum of the tau burden in the core regions involved in the disease, we propose a simple staging system: stage 1 mild neurodegeneration without overt or only minimal tau pathology, stage 2 moderate neurodegeneration and mild/ moderate tauopathy and stage 3 prominent neurodegeneration and tau pathology. This staging intends to reflect a potential (age- and time-dependent) progression of tau pathology, supporting the current notion that tau accumulation is a secondary phenomenon related to the presence of anti-IgLON5 antibodies in the CNS. Finally, we adapt the original research criteria of the anti-IgLON5 disease-related tauopathy to include the spectrum of pathologies observed in this larger postmortem series.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
- Comprehensive Center for Clinical Neurosciences & Mental Health Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
- Sleep Unit, Neurology Department, Hospital Clinic de Barcelona, IDIBAPS/FCRB, Barcelona, Spain.
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (FCRB-IDIBAPS), Neuroimmunology Program, Barcelona, Spain.
- Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS/FCRB), Neurological Tissue Bank of the Biobanc, Hospital Clinic, Barcelona, Spain.
- Memory Unit, Neurology Department, Hospital Clinic de Barcelona, IDIBAPS/FCRB, Barcelona, Spain.
ORCID-Profile: Ellen Gelpi
Förderung
- Austrian Science Fund
- Bundesministerium für Bildung und Forschung
- Instituto de Salud Carlos III
- Horizon 2020 Framework Programme
- Tekniikan Akatemia
- Helsingin Yliopisto
- Medical University of Vienna
Zitieren
APA
Gelpi, E., Reinecke, R., Gaig, C., Iranzo, A., Sabater, L., Molina-Porcel, L., Aldecoa, I., Endmayr, V., Högl, B., Schmutzhard, E., Poewe, W., Pfausler, B., Popovic, M., Pretnar-Oblak, J., Leypoldt, F., Matschke, J., Glatzel, M., Erro, E. M., Jerico, I., …, & Höftberger, R. (2024). Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy. Acta Neuropathologica, 148(1). https://doi.org/10.1007/s00401-024-02805-y
Vancouver
Gelpi E, Reinecke R, Gaig C, Iranzo A, Sabater L, Molina-Porcel L, et al. Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy. Acta Neuropathologica. 2024;148(1). doi:10.1007/s00401-024-02805-y
BibTeX
@article{Gelpi2024,
author = {Gelpi, Ellen and Reinecke, Raphael and Gaig, Carles and Iranzo, Alex and Sabater, Lidia and Molina-Porcel, Laura and Aldecoa, Iban and Endmayr, Verena and Högl, Birgit and Schmutzhard, Erich and Poewe, Werner and Pfausler, Bettina and Popovic, Mara and Pretnar-Oblak, Janja and Leypoldt, Frank and Matschke, Jakob and Glatzel, Markus and Erro, Elena Maria and Jerico, Ivonne and Caballero, Maria Cristina and Zelaya, Maria Victoria and Mariotto, Sara and Heidbreder, Anna and Kalev, Ognian and Weis, Serge and Macher, Stefan and Berger-Sieczkowski, Evelyn and Ferrari, Julia and Reisinger, Christoph and Klupp, Nikolaus and Tienari, Pentti and Rautila, Osma and Niemelä, Marja and Yilmazer-Hanke, Deniz and Guasp, Mar and Bloem, Bas and Van Gaalen, Judith and Kusters, Benno and Titulaer, Maarten and Fransen, Nina L and Santamaria, Joan and Dawson, Thimoty and Holton, Janice L and Ling, Helen and Revesz, Tamas and Myllykangas, Liisa and Budka, Herbert and Kovacs, Gabor G and Lewerenz, Jan and Dalmau, Josep and Graus, Francesc and Koneczny, Inga and Höftberger, Romana},
title = {Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy},
journal = {Acta Neuropathologica},
year = {2024},
volume = {148},
number = {1},
doi = {10.1007/s00401-024-02805-y}
}
EUVIMED